Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis

Reconstitution of circulating lymphocyte counts in FTY720-treated MS patients

(2010) Trina A. Johnson et al.   CLINICAL IMMUNOLOGY

T helper type 1 and 17 cells determine efficacy of interferon-β in multiple sclerosis and experimental encephalomyelitis

(2010) Robert C Axtell et al.   NATURE MEDICINE

Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis

(2010) M. Mehling et al.   NEUROLOGY

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

(2010) Jeffrey A. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE

International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid Receptor Nomenclature

(2010) J. Chun et al.   PHARMACOLOGICAL REVIEWS

FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation

(2010) J. W. Choi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system

(2009) Volker Brinkmann   BRITISH JOURNAL OF PHARMACOLOGY

Neuroprotection and neuroregeneration in multiple sclerosis

(2009) Martin Stangel   JOURNAL OF NEUROLOGY

FTY720 ameliorates MOG-induced experimental autoimmune encephalomyelitis by suppressing both cellular and humoral immune responses

(2009) Dimitrios Papadopoulos et al.   JOURNAL OF NEUROSCIENCE RESEARCH

Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors

(2009) Florian Mullershausen et al.   Nature Chemical Biology

Chemical modulators of sphingosine-1-phosphate receptors as barrier-oriented therapeutic molecules

(2009) David Marsolais et al.   NATURE REVIEWS DRUG DISCOVERY

Incomplete Inhibition of Sphingosine 1-Phosphate Lyase Modulates Immune System Function yet Prevents Early Lethality and Non-Lymphoid Lesions

(2009) Peter Vogel et al.   PLoS One

Treatment with Immunosuppressants FTY720 and Tacrolimus Promotes Functional Recovery after Spinal Cord Injury in Rats

(2009) Jie Zhang et al.   TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE

Cyclical and Dose-Dependent Responses of Adult Human Mature Oligodendrocytes to Fingolimod

(2008) Veronique E. Miron et al.   AMERICAN JOURNAL OF PATHOLOGY

Astrocytes in multiple sclerosis: A product of their environment

(2008) A. Nair et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Sphingosine kinase 1/S1P receptor signaling axis controls glial proliferation in mice with Sandhoff disease

(2008) Yun-Ping Wu et al.   HUMAN MOLECULAR GENETICS

Central nervous system-directed effects of FTY720 (fingolimod)

(2008) Veronique E. Miron et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis

(2008) M. Mehling et al.   NEUROLOGY

FTY720 modulates human oligodendrocyte progenitor process extension and survival

(2007) Veronique E. Miron et al.   ANNALS OF NEUROLOGY

Brain sphingosine-1-phosphate receptors: Implication for FTY720 in the treatment of multiple sclerosis

(2007) Kumlesh K. Dev et al.   PHARMACOLOGY & THERAPEUTICS